Current News

Print version | Send article | RSS feed

Senetek PLC Acquires Rights to Anticancer Technology for the Treatment of Brain Tumors Using Interference RNA

09 Nov 2006 - Senetek PLC announced agreements with the Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poznan, Poland for the exclusive rights to anticancer technology for the treatment of brain tumors using interference RNA, as well as exclusive rights to three compounds for the treatment of skin aging.
 
The collaboration with the Institute of Bioorganic Chemistry of the Polish Academy of Sciences will provide Senetek three new compounds with differentiating benefits for treating skin aging and possibly other aging conditions through their use in licensed cosmeceutical, nutritional and prescription products.
 
In addition, Senetek has acquired the rights to technology developed by the Institute in cooperation with Department of Neurosurgery and Neurotraumatology University of Medical Sciences in Poznan, Poland for the treatment of human brain tumors using RNA interference to inhibit the production of tenascin-C, whose expression has been suggested to correlate with the grade of malignancy of brain tumors. Recently this new technology has been applied to the treatment of several patients with glioblastoma multiforme, a common form of brain tumor, with resounding success.
 
Under the terms of the collaborative agreement, Senetek will have rights for all applications of the in-licensed technologies in exchange for undisclosed royalty payments to be paid to the Institute upon commercialization.